Results 51 to 60 of about 7,936 (162)

Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies

International Journal of COPD, 2014
Richard ZuWallack,1 Lisa Allen,2 Gemzel Hernandez,2 Naitee Ting,2 Roger Abrahams3 1Saint Francis Hospital and Medical Center, Hartford, CT, USA; 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; 3Morgantown Pulmonary Associates, Morgantown,
ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R   +4 more
doaj  

Effectiveness of COPD treatment with the combination of tiotropium/olodaterol in Polish standard clinical practice as measured by the improvement of CCQ: an observational study [PDF]

, 2022
Aleksander Kania, Natalia Celejewska-Wójcik, Katarzyna Żurowska, Adam Barczyk   +3 more
openalex   +1 more source

Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 9, Page 1576-1587, September 2025.
This large‐scale, propensity‐matched retrospective cohort study provides evidence that dupilumab treatment during pregnancy is not associated with an elevated risk of maternal adverse pregnancy outcomes (APOs). By utilizing real‐world data, it contributes critical insights into dupilumab's safety profile in pregnant women, addressing a crucial gap in ...
Sophie L. Preuß, Katja Bieber, Artem Vorobyev, Andreas Recke, Eva Lotta Moderegger, Henner Zirpel, Evelyn Gaffal, Diamant Thaçi, Khalaf Kridin, Ralf J. Ludwig   +9 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, Volume 27, Issue 8, Page 1444-1458, August 2025.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +16 more
wiley   +1 more source

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium

International Journal of COPD, 2010
Donald P TashkinDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA,Los Angeles, CA, USAAbstract: The course of COPD is punctuated by acute exacerbations that are associated with an increase ...
Donald P Tashkin
doaj  

Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients

Journal of Asthma and Allergy, 2021
Stefan Zielen,1 Gianna Reichert,1 Helena Donath,1 Jordis Trischler,1 Johannes Schulze,1 Olaf Eickmeier,1 Martin Eckrich,2 Katharina Blumchen1 1Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic Fibrosis, University ...
Zielen S, Reichert G, Donath H, Trischler J, Schulze J, Eickmeier O, Eckrich M, Blumchen K   +7 more
doaj  

Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis

International Journal of COPD, 2015
David MG Halpin,1 Ronald Dahl,2 Christoph Hallmann,3 Achim Mueller,3 Donald Tashkin4 1NHS SW, Royal Devon and Exeter Hospital, Exeter, Devon, England, UK; 2Allergy Centre, Odense University Hospital, Odense, Denmark; 3Boehringer Ingelheim Pharma GmbH ...
Halpin DMG, Dahl R, Hallmann C, Mueller A, Tashkin D   +4 more
doaj  

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium

Respiratory Research, 2012
Randomised, double-blind, controlled trials are considered the gold standard for evaluating a pharmacological agent, as they minimise any potential bias.
Beeh Kai-Michael, Beier Jutta, Donohue James F   +2 more
doaj   +1 more source

Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions

BMC Pulmonary Medicine, 2010
Background Tiotropium is reimbursed since March 2004 in Belgium for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Questions however remain on this product's value for money.
Thiry Nancy, Devriese Stephan, Neyt Mattias, Van den Bruel Ann   +3 more
doaj   +1 more source

Impact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene

, 2022
Kostiantyn Dmytriiev, Yuriy Mostovoy, Nataliia Slepchenko   +2 more
openalex   +2 more sources